Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study
Open accessAbstract
A multicenter, double-blind, randomized study was conducted to assess the effect of caffeine on regadenoson stress myocardial perfusion imaging (MPI). Subjects with a high likelihood of coronary artery disease underwent a rest single-photon emission computed tomography MPI on day 1 (MPI-1) and a stress MPI with regadenoson on day 3 (MPI-2). Individuals with ≥1 segment with a reversible defect received double-blind caffeine tablets (200 or 400 mg) or placebo 90 min before a repeat regadenoson stress MPI (MPI-3) on day 5. Overall, 207 subjects completed the study (caffeine 200 mg, n = 70; caffeine 400 mg, n = 71; placebo, n = 66). The mean number of segments with reversible defects decreased from MPI-2 to MPI-3 in the caffeine 200 and 400 mg groups versus no significant change in the placebo group [mean ± standard deviation: -0.61 ± 1.097, -0.62 ± 1.367, and 0.12 ± 0.981, respectively (overall treatment effect, P < 0.001)]. The majority of subjects who received caffeine shifted to a lower ischemia size category from MPI-2 to MPI-3, with no clear pattern observed in subjects who received placebo. For caffeine exposed patients with ≥3 segments with reversible defects at MPI-2, 21/23 had fewer detected at MPI-3. Both the 200 and 400 mg doses of caffeine significantly reduced the number of segments with reversible defects detected by regadenoson stress MPI.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tejani et al. 2014 showed that doses of caffeine of 200 mg and 400 mg significantly decreased the number of cardiac segments with reversible vascularisation defects, suggesting that caffeine at doses of 200 mg or greater could significantly counteract the vasodilator effect of regadenoson in the coronary arteries in patients with coronary artery disease.
“a similar study using regadenoson stress-single-photon emission computed tomography (SPECT) MPI in patients with CAD showed that doses of caffeine of 200 mg and 400 mg significantly decreased the number of cardiac segments with reversible vascularisation defects, suggesting that caffeine at doses of 200 mg or greater could significantly counteract the vasodilator effect of regadenoson in the”
From Scientific Opinion on the safety of caffeine (2015) · cites this paper as Tejani et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart
Cerqueira, M. D., Weissman, N. J., Dilsizian, V., Jacobs, A. K., Kaul, S., Laskey, W. K., Pennell, D. J., Rumberger, J. A., Ryan, T., & Verani, M. S. (2002) · Circulation · doi:10.1161/hc0402.102975 · Cited by 7,043 · see citing works
The International Classification of Headache Disorders: 2nd edition
Olesen, J., Goadsby, P. J., & Steiner, T. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00590-8 · Cited by 5,046 · see citing works
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · see citing works
Olesen, J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2003.00824.x · Cited by 2,056 · see citing works
Temporal Trends in the Frequency of Inducible Myocardial Ischemia During Cardiac Stress Testing
Rozanski, A., Gransar, H., Hayes, S. W., Min, J. K., Friedman, J. D., Thomson, L., & Berman, D. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.056 · Cited by 355 · see citing works
Iskandrian, A. E., Bateman, T. M., Belardinelli, L., Blackburn, B. K., Cerqueira, M. D., Hendel, R. C., Lieu, H. D., Mahmarian, J. J., Olmsted, A., Underwood, S. R., et al. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.06.114 · Cited by 347 · see citing works
Cerqueira, M. D., Nguyen, P. K. P., Staehr, P., Underwood, S. R., & Iskandrian, A. E. (2008) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.02.003 · Cited by 243 · see citing works
Regadenoson: A New Myocardial Stress Agent
Jaroudi, W. A. A., & Iskandrian, A. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.089 · Cited by 219 · see citing works
A <sub>2A</sub> -Adenosine Receptor Reserve for Coronary Vasodilation
Shryock, J. C., Snowdy, S., Baraldi, P. G., Cacciari, B., Spalluto, G., Monopoli, A., Ongini, E., Baker, S. P., & Belardinelli, L. (1998) · Circulation · doi:10.1161/01.cir.98.7.711 · Cited by 199 · see citing works
The A2A Adenosine Receptor Mediates Coronary Vasodilation
Belardinelli, L., Shryock, J. C., Snowdy, S., Zhang, Y., Monopoli, A., Lozza, G., Ongini, E., Olsson, R. A., & Dennis, D. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37317-3 · Cited by 186 · see citing works
Hendel, R. C., Bateman, T. M., Cerqueira, M. D., Iskandrian, A. E., Leppo, J. A., Blackburn, B., & Mahmarian, J. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.097 · Cited by 128 · see citing works
Prenner, B. M., Bukofzer, S., Behm, S., Feaheny, K., & McNutt, B. E. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9547-4 · Cited by 81 · see citing works
Self-citationCaffeine Analogs: Structure-Activity Relationships at Adenosine Receptors
Daly, J. W., Hide, I., ller, C. E. M. U., & Shamim, M. T. (2008) · Pharmacology · doi:10.1159/000138813 · Cited by 65 · see citing works
Zoghbi, G. J., Htay, T., Aqel, R. A., Blackmon, L., Heo, J., & Iskandrian, A. E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.088 · Cited by 65 · see citing works
Shapiro, R. E. (2007) · Neurological Sciences · doi:10.1007/s10072-007-0773-5 · Cited by 53 · see citing works
Gaemperli, O., Schepis, T., Koepfli, P., Siegrist, P. T., Fleischman, S., Nguyen, P., Olmsted, A., Wang, W., Lieu, H., & Kaufmann, P. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.014 · Cited by 52 · cited 1× · see citing works
“A previous study showed that moderate oral caffeine intake (200 mg) did not significantly affect regadenoson-induced myocardial blood flow as assessed by positron emission tomography (PET) in 41 healthy individuals [9].”
BackgroundAnanthasubramaniam, K., Weiss, R., McNutt, B. E., Klauke, B., Feaheny, K., & Bukofzer, S. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9508-3 · Cited by 43 · see citing works
Self-citationTejani, F. H., Thompson, R. C., Iskandrian, A. E., McNutt, B. E., & Franks, B. (2010) · Journal of Nuclear Cardiology · doi:10.1007/s12350-010-9311-6 · Cited by 16 · see citing works
Self-citation“One” Cup of Coffee and Nuclear SPECT to Go
Bangalore, S., Parkar, S., & Messerli, F. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.044 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers
Henzlova, M. J., Duvall, W. L., Einstein, A. J., Travin, M. I., & Verberne, H. J. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0387-x · Cited by 700 · see citing works
Scientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613 · see citing works
“However, a similar study using regadenoson stress- single-photon emission computed tomography (SPECT) MPI in patients with CAD showed that doses of caffeine of 200 mg and 400 mg significantly decreased the number of cardiac segments with reversible vascularisation defects, suggesting that caffeine at doses of 200 mg o…”
Effects of Caffeine on Myocardial Blood Flow: A Systematic Review
van Dijk, R., Ties, D., Kuijpers, D., van der Harst, P., & Oudkerk, M. (2018) · Nutrients · doi:10.3390/nu10081083 · Cited by 28 · see citing works
van Dijk, R., Kuijpers, D., Kaandorp, T. A. M., van Dijkman, P. R. M., Vliegenthart, R., van der Harst, P., & Oudkerk, M. (2017) · International journal of cardiac imaging · doi:10.1007/s10554-017-1157-4 · Cited by 27 · see citing works
Im, D. J., Hong, S. J., Park, E., Kim, E. Y., Jo, Y., Kim, J., Park, C. H., Yong, H. S., Lee, J. W., Hur, J. H., et al. (2019) · Korean Journal of Radiology · doi:10.3348/kjr.2019.0411 · Cited by 22 · see citing works
Doran, J. A., Sajjad, W., Schneider, M. D., Gupta, R., Mackin, M. L., & Schwartz, R. G. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0452-0 · Cited by 20 · see citing works
RetractedHealth Literacy and Patient Preparation in Radiology
Goguen, J. (2016) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2016.06.002 · Cited by 17 · see citing works
Saab, R., Bajaj, N. S., & Hage, F. G. (2015) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0364-4 · Cited by 16 · see citing works
Kero, T., Saraste, A., Lagerqvist, B., Sörensen, J., Pikkarainen, E., Lubberink, M., & Knuuti, J. M. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02731-6 · Cited by 12 · see citing works
Caffeine reduces the sensitivity of vasodilator MPI for the detection of myocardial ischaemia: Pro
Reyes, E. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0371-5 · Cited by 11 · see citing works
Tanaka, H., Matsumoto, H., Takahashi, H., Hosonuma, M., Sato, S., Ogura, K., Oishi, Y., Masaki, R., Sakai, K., Sekimoto, T., et al. (2021) · EuroIntervention · doi:10.4244/eij-d-21-00453 · Cited by 9 · see citing works
Pitfalls and Limitations of Radionuclide and Hybrid Cardiac Imaging
Travin, M. I. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.02.003 · Cited by 9 · see citing works
Jolly, A. F., & Thomas, G. S. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0484-5 · Cited by 9 · see citing works
Rischpler, C., & Totzeck, M. (2018) · Journal of Nuclear Cardiology · doi:10.1007/s12350-018-1332-6 · Cited by 9 · see citing works
How to assess nonresponsiveness to vasodilator stress
Lim, P., Agarwal, V., & Patel, K. (2024) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2024.101850 · Cited by 8 · see citing works
Regadenoson Stress for Myocardial Perfusion Imaging
Reyes, E. (2015) · Future Cardiology · doi:10.2217/fca.15.70 · Cited by 8 · see citing works
Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson
Bitar, A., Mastouri, R. A., & Kreutz, R. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130487 · Cited by 8 · see citing works
Shinn, K., Henderson, C. S., Schenone, A. L., Goonewardena, S. N., Shore, S., Murthy, V. L., & Madamanchi, C. (2025) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2025.102174 · Cited by 5 · see citing works
Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
Muñiz, J., Ezponda, A., Caballeros, M., de la Fuente, A., Gavira, J. J., & Bastarrika, G. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02877-z · Cited by 5 · see citing works
Lee, C., Dennett, A. M., Pinson, J., & Lewis, A. K. (2024) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2023.12.011 · Cited by 5 · see citing works
Caffeine does not significantly reduce the sensitivity of vasodilator stress MPI: Rebuttal
Reyes, E. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0421-7 · Cited by 5 · see citing works
Posch, M. I., Kay, M. D., Harhash, A. A., Huang, J. J., Krupinski, E. A., Abidov, A., McMillan, N. A., & Kuo, P. H. (2019) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.118.225219 · Cited by 4 · see citing works
Christian, T. F. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0412-8 · Cited by 3 · see citing works
Caffeine and Cardiovascular Outcomes: Current Evidence and Clinical Perspectives
Neshat, N., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001252 · Cited by 2 · see citing works
Noninvasive Diagnostic Modalities for the Evaluation of Coronary Artery Disease
Jain, D., & Aronow, W. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00011-5 · Cited by 2 · see citing works
Smith, M. F. (2022) · Journal of Nuclear Cardiology · doi:10.1007/s12350-022-02954-1 · Cited by 2 · see citing works
Adenosine–caffeine: the agonist—antagonist couple for vasodilator stress tests
Songy, B. (2022) · Journal of Nuclear Cardiology · doi:10.1007/s12350-022-03107-0 · Cited by 2 · see citing works
Timing of Regadenoson-Induced Peak Hyperemia and the Effects on Coronary Flow Reserve
Kattapuram, N., Shadman, S., Morgan, E. E., Benton, C., Awojoodu, S., Kim, D., Ramos, J., Barac, A., Bandettini, W. P., Kellman, P., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.08.010 · Cited by 1 · see citing works
Duvall, W. L., Skali, H., Aggarwal, N. R., Boczar, K. E., Calnon, D. A., Chareonthaitawee, P., Doukky, R., Einstein, A. J., Hage, F. G., Hutt, E., et al. (2026) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2026.102970 · Cited by 1 · see citing works
Im, D. J., Hong, S. J., Park, E., Kim, E. Y., Jo, Y., Kim, J. J., Park, C. H., Yong, H. S., Lee, J. W., Hur, J. H., et al. (2020) · Investigative Magnetic Resonance Imaging · doi:10.13104/imri.2020.24.1.1 · Cited by 1 · see citing works
Im, D. J., Hong, S. J., Park, E., Kim, E. Y., Jo, Y., Kim, J., Park, C. H., Yong, H. S., Lee, J. W., Hur, J. H., et al. (2020) · Cardiovascular Imaging Asia · doi:10.22468/cvia.2019.00171 · Cited by 1 · see citing works
Cardiovascular imaging 2014 in the International Journal of Cardiovascular Imaging
Bezerra, H. G., da Costa, R. A., Reiber, J. H. C., Schoenhagen, P., Stillman, A. A., SUTTER, J. D., & de Veire, N. V. (2015) · International journal of cardiac imaging · doi:10.1007/s10554-015-0627-9 · Cited by 1 · see citing works
Regadenoson — Overview of Applications in Cardiology
Palani, G., Baumann, R., & Ananthasubramaniam, K. (2015) · InTech eBooks · doi:10.5772/61154
Andrikopoulou, E., Iskandrian, A. E., & Hage, F. G. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780190095659.003.0012
Measurement of Myocardial Blood Flow by SPECT
Brito, J. B. D. O., Small, G. R., Ascah, K. J., Wells, R. G., & Ruddy, T. D. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780190095659.003.0010
Nuclear Cardiology Report Generation
AlJaroudi, W. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780190095659.003.0036
Prognostic Value of Regadenoson Stress Perfusion CMR
Muñiz, J., Ezponda, A., Caballeros, M., de la Fuente, A., Salterain-González, N., & Bastarrika, G. (2026) · Medical Sciences · doi:10.3390/medsci14020190
- Authors
- Tejani, F. H., Thompson, R. C., Kristy, R., & Bukofzer, S.
- Affiliations
- Saint Luke's Hospital (US)
- Astellas Pharma (United States) (US)
- Corresponding author
- Tejani, Furqan H.
- Venue
- The International Journal of Cardiovascular Imaging
- Published
- 2014-04-17
- Volume
- 30
- Issue
- 5
- Pages
- 979-989
- ISSN
- 0167-9899 (ISSN-L)
- 1569-5794
- 1573-0743
- PMC
- PMC4008779
- OpenAlex
- W1964070671
- Cited by
- 37
- References
- 19
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 6 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 8 · 2015: 7
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- International journal of cardiac imaging (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- Astellas Pharma Global Development
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Health Sciences › Medicine › Pharmacology › Coffee research and impacts
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- caffeine, regadenoson, myocardial perfusion imaging, SPECT, pharmacological stress, coronary artery disease, reversible myocardial ischemia, coronary artery disease severity
- MeSH terms
- Adult, Aged, Aged, 80 and over, Caffeine, Coronary Disease, Double-Blind Method, Exercise Test, Female, Humans, Image Interpretation, Computer-Assisted, Male, Middle Aged, Prospective Studies, Purines, Pyrazoles, Tomography, Emission-Computed, Single-Photon, Adenosine A2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
